BioCentury’s 2021 class of emerging companies
An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
The class of innovators in BioCentury’s 2021 Emerging Company Profiles showcases evolving approaches to overcoming the challenges of new modalities.
The collection, which includes 118 start-ups, focuses on private biopharmas developing novel platforms or building first-in-class or best-in-class pipelines, that typically have emerged from stealth or raised their first venture rounds in the past three years. The series represents a curated group of companies with compelling science, rather than a comprehensive collection of newcos...